Mike Bastian

14PUBLICATIONS
25CO-AUTHORS
PharmacogenomicsMajor global burdens of diseaseInfant and child healthApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 01, 2026
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.

|Apr 17, 2026
Identifying the Most Relevant Eczema Area and Severity Index Thresholds from the Patient Perspective in Atopic Dermatitis Treatment.

|Apr 02, 2026
Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Amy S Paller, Andreas Pinter, Lara Wine Lee

|Jan 21, 2026
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.

Eric L Simpson, Robert Bissonnette, Mette Deleuran

|Dec 29, 2025
A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".

Sonja Ständer, Andreas Pinter, Firas G Hougeir

|Sep 19, 2025
Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.

Sonja Ständer, Gil Yosipovitch, Brian S Kim

Pageof 3

Frequent Collaborators

3 joint publications

Diamant Thaçi

3 joint publications

Eric L Simpson

2 joint publications

Matthias Augustin

2 joint publications

Ana B Rossi